Featured Studies Results
Cancer: Breast
Research Study on the Genetics of Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer
Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328 /treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)
Treatment
Treatment study for people with advanced or metastatic cancers
Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)
https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle
Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)
Treatment
Post-treatment study to monitor for recurrence
Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T
https://www.facingourrisk.org/research-clinical-trials/study/364 /treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t
Clinicaltrials.gov identifier:
NCT06878248 (https://clinicaltrials.gov/show/NCT06878248)
Treatment
Phase 1 treatment study for people with advanced solid tumors
An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)
https://www.facingourrisk.org/research-clinical-trials/study/385 /an-early-detection-and-prevention-study-for-people-with-an-increased-risk-of-cancer-inadvance
Clinicaltrials.gov identifier:
NCT05463796 (https://clinicaltrials.gov/show/NCT05463796)
Prevention
Study for people at risk of cancer, including previvors, survivors and family members
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363 /testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359 /study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2
Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)
Treatment
Phase 1 treatment study for metastatic solid tumors
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression
https://www.facingourrisk.org/research-clinical-trials/study/352 /an-online-program-to-help-asian-american-breast-cancer-survivors-manage-pain-and-depression
Clinicaltrials.gov identifier:
NCT06085313 (https://clinicaltrials.gov/show/NCT06085313)
Quality of Life
An online program to help Asian American breast cancer survivors manage pain and depression
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350 /treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Clinicaltrials.gov identifier:
NCT06167317 (https://clinicaltrials.gov/show/NCT06167317)
Treatment
Treatment study for people with advanced or metastatic solid tumors
HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/342 /heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer
Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)
Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)
Treatment
Biomarker study for people with early-stage breast cancer
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT05929768 (https://clinicaltrials.gov/show/NCT05929768)
Treatment
Treatment study for early-stage triple-negative breast cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.